Advertisement
News
Subscribe to MDT Magazine News

Marinus Pharmaceuticals Announces Commencement of Phase 2 Trial of Ganaxolone for the Treatment of Posttraumatic Stress Disorder

April 21, 2011 6:35 am | by Bio-Medicine.Org | Comments

BRANFORD, Conn., April 21, 2011 /- Marinus Pharmaceuticals, Inc., the leader in the development of neurosteroids for central nervous system disorders, today announced commencement of a proof-of-concept clinical trial of its lead candidate ganaxolone for the treatment of posttraumatic...

TOPICS:

Sanare and BrightSky Announce National Strategic Partnership with American Diabetes Association

April 21, 2011 6:35 am | by Bio-Medicine.Org | Comments

RENO, Nev., April 21, 2011 /- Sanare, LLC, a leading provider of care management solutions for people with diabetes, and its new consumer brand, BrightSky, have become National Strategic Partners of the American Diabetes Association.® (Logo:...

TOPICS:

ORTHOCON® Receives CE Mark and Health Canada Medical Device License for HEMASORB®

April 21, 2011 6:34 am | by Bio-Medicine.Org | Comments

IRVINGTON, N.Y., April 21, 2011 /- ORTHOCON, Inc., a privately-held therapeutic device company, today announced that DEKRA and Health Canada have cleared its HEMA SORB Absorbable Bone Hemostat Matrix for clinical use and sale in Europe and Canada. HEMA SORB is a ready-to-use,...

TOPICS:
Advertisement

Amgen says it will pay dividend starting in 2Q

April 21, 2011 5:45 am | by The Associated Press | Comments

Biotechnology company Amgen Inc. says it will start paying a quarterly dividend in the second quarter, and plans to pay about 20 percent of its adjusted annual profit in dividends.The Thousand Oaks, Calif., company had been expected to declare its first dividend. It says it will raise its...

Biogen Q1 numbers up on strength of MS drug sales

April 21, 2011 5:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Biogen Idec Inc. said first-quarter revenue was up 9 percent over the same period a year earlier, driven by the performance of its two blockbuster multiple sclerosis infusion treatments.

Reportlinker Adds Medical Equipment Monthly Deals Analysis - M & A and Investment Trends, April 2011

April 21, 2011 5:32 am | by Bio-Medicine.Org | Comments

NEW YORK, April 21, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Medical Equipment Monthly Deals Analysis - M&A and Investment Trends, April 2011...

TOPICS:

Tooling U Relocates to New Brick and Mortar Site

April 21, 2011 4:37 am | by Society of Manufacturing Engineers | Comments

CLEVELAND, Ohio, April 21, 2010 — Tooling U, the leading developer of online manufacturing training, has relocated its headquarters to Tyler Village — one of Cleveland's largest-ever downtown redevelopment projects. More

Brooks sells Oregon unit to Celestica for $80M

April 21, 2011 4:36 am | by Mass High Tech: The Journal of New England Technology | Comments

Chelmsford semiconductor technology maker Brooks Automation Inc. has decided to sell a contract manufacturing business unit based in Oregon for $80 million in cash to Canadian firm Celestica Inc.

Advertisement

UnitedHealth's 1Q profit climbs 13 percent

April 21, 2011 2:45 am | by The Associated Press | Comments

UnitedHealth Group says its first-quarter net income rose 13 percent, led by revenue gains in commercial health insurance. The managed care company also raised its full-year earnings forecast.The Minnetonka, Minn., insurer says it earned $1.34 billion, or $1.22 per share, in the three months...

Reportlinker Adds Europe ENT Devices Market Outlook to 2017

April 21, 2011 2:33 am | by Bio-Medicine.Org | Comments

NEW YORK, April 21, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Europe ENT Devices Market Outlook to 2017 http://www.reportlinker.com/p0333693/Europe-ENT-Devices-Market-Outlook-to-2017.html Europe ENT Devices Market Outlook to 2017...

TOPICS:

Reportlinker Adds Medical Equipment Annual Deals Analysis 2011

April 21, 2011 1:34 am | by Bio-Medicine.Org | Comments

NEW YORK, April 21, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Medical Equipment Annual Deals Analysis 2011 http://www.reportlinker.com/p0180789/Medical-Equipment-Annual-Deals-Analysis-2011.html Medical Equipment Annual Deals...

TOPICS:

Amgen and UCB Announce Positive Phase 2 Results of AMG 785/CDP7851 in Patients With Postmenopausal Osteoporosis (PMO)

April 20, 2011 9:36 pm | by Bio-Medicine.Org | Comments

THOUSAND OAKS, Calif. and BRUSSELS, April 21, 2011 /- Amgen (NASDAQ: AMGN ) and UCB (Euronext Brussels: UCB) announced today positive top-line results from their Phase 2 clinical study comparing sclerostin-antibody AMG 785/CDP7851 to placebo in postmenopausal women with low bone mineral...

TOPICS:

Summary Box: Amgen reports 1Q financial results(2)

April 20, 2011 3:46 pm | by The Associated Press | Comments

FINANCIAL RESULTS: Amgen Inc. said its profit fell 4 percent on higher costs, but adjusted profit and revenue topped Wall Street expectations.COSTS: The higher costs came mainly from marketing for the company's newly launched bone drugs, called Prolia and Xgeva, and for shifting three products to...

Summary Box: Amgen reports 1Q financial results

April 20, 2011 3:45 pm | Comments

FINANCIAL RESULTS: Amgen Inc. said its profit fell 4 percent on higher costs, but adjusted profit and revenue topped Wall Street expectations.COSTS: The higher costs came mainly from marketing for the company's newly launched bone drugs, called Prolia and Xgeva, and for shifting three products to...

Dynavax to get $6 million payment from Glaxo

April 20, 2011 1:45 pm | by The Associated Press | Comments

Biotechnology company Dynavax Technologies Corp. said Wednesday it will receive a $6 million milestone payment from partner GlaxoSmithKline after it started a study on a potential lupus drug.Dynavax started early-stage testing on DV1179. The Phase 1 clinical trial is aimed at testing safety and...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading